Adipose-derived stem cells (ADSCs) are multipotent cells with a high capacity for self-renewal. They are ideal for regenerative therapy applications. ADSCs can differentiate into specialized cells of the body such as osteocytes, adipocytes, neural cells, vascular endothelial cells, cardiomyocytes, pancreatic β-cells, and hepatocytes. Their easy accessibility, low immunogenicity and their ability to secrete trophic factors, cytokines and chemokines make them the favorable cell type for experimental and clinical use. ADSCs are also demonstrated to have proangiogenic, immunomodulatory, anti-apoptotic, anti-inflammatory, and anti-scarring effects. Many trials are underway to understand the potential of these cells to use for a wide range of clinical conditions including skeletal tissue repair, ischemic injuries, myocardial infarction, soft tissue regeneration and immune disorders such as lupus, arthritis, Crohn’s disease, multiple sclerosis, diabetes mellitus, and graft-versus-host disease.
These ADSCs were isolated from young adult (12 week) female Sprague Dawley rat adipose tissue. The cells are cultured, passaged for purity, cryopreserved, and delivered frozen. Each vial contains 1 x 106 cells in 1 mL volume. Cells are characterized by flow cytometry for CD90, CD105, CD44, CD29, CD45, and CD34 and are negative for mycoplasma, yeast, fungi, and bacteria. Cells are assured to further culture using the protocol provided by JangoCell.